Moderate Interaction
ARIPIPRAZOLE/FLUOXETINE; PAROXETINE
Abilify Oral and Prozac Oral may interact based on the potential interaction between ARIPIPRAZOLE and FLUOXETINE; PAROXETINE.
Aripiprazole/Fluoxetine; Paroxetine
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
MONOGRAPH TITLE: Aripiprazole/Fluoxetine; Paroxetine
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Fluoxetine and paroxetine may inhibit the metabolism of aripiprazole by CYP P-450-2D6.(1)
CLINICAL EFFECTS: Concurrent administration of fluoxetine or paroxetine with aripiprazole may result in elevated levels of aripiprazole and signs of toxicity.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of aripiprazole states that the dose of aripiprazole should be reduced to one-half of its normal dose when fluoxetine or paroxetine are coadministered, unless aripiprazole is being administered as adjunctive therapy for Major Depressive Disorder. If fluoxetine or paroxetine therapy is discontinued, the dose of aripiprazole should be increased.(1)
DISCUSSION: The administration of quinidine (166 mg daily for 13 days) with a single dose of aripiprazole (10 mg) resulted in a 112% increase in the area-under-curve (AUC) of aripiprazole and a 35% decrease in the AUC of dehydro-aripiprazole, the active metabolite of aripiprazole. Fluoxetine and paroxetine, which are also potent inhibitors of CYP P-450-2D6, are expected to interact similarly.(1)
REFERENCE:
1.Abilify (aripiprazole) US prescribing information. Otsuka America Pharmaceutical, Inc. July, 2009.